GSEP
IMNM icon

Golden State Equity Partners’s Immunome IMNM Stock Holding History

Golden State Equity Partners’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.8K Buy
+950
New +$21.1K ﹤0.01% 1085

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Golden State Equity Partners's IMNM Position: Q1 2026 in Review

Golden State Equity Partners opened a new position in Immunome (IMNM) in Q1 2026: 950 shares worth $20.8K. The stake represents ﹤0.01% of the portfolio and ranks #1085 among its holdings.

200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Golden State Equity Partners held 950 shares of Immunome worth $20.8K as of Q1 2026.
  • Immunome was a new Golden State Equity Partners position in Q1 2026.
  • Immunome made up ﹤0.01% of Golden State Equity Partners's portfolio in Q1 2026, its #1085 holding.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Golden State Equity Partners's 13F filing for Q1 2026, filed 28 Apr 2026.